• Теги
    • избранные теги
    • Компании2842
      • Показать ещё
      Разное728
      • Показать ещё
      Страны / Регионы382
      • Показать ещё
      Международные организации42
      • Показать ещё
      Люди108
      • Показать ещё
      Формат40
      Показатели101
      • Показать ещё
      Издания21
      • Показать ещё
Gilead Sciences
22 марта, 16:30

Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen

Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen

22 марта, 15:33

Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results

Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.

21 марта, 23:22

Mylan Receives Tentative Approval from FDA for HIV Therapy

Mylan N.V. (MYL) obtained a tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for the New Drug Application for cocktail therapy Sustiva, lamivudine and Viread, 400 mg/300 mg/300 mg (TLE400).

21 марта, 14:00

Biotech Bull Making a Comeback

Biotech Bull Making a Comeback

20 марта, 17:06

Why Biotech Stock Gilead (GILD) Could Be a Value Trap

Gilead's (GILD) valuation looks compelling but is the company really poised for

16 марта, 15:46

Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data

The biotech sector reacted favorably to President Donald Trump's pick for the top post in the FDA.

16 марта, 00:40

Forget Gilead, Buy These Small-Cap Biotech Stocks Instead

At this juncture, we advise investors to forget Gilead (GILD), a Zacks Rank #4 (Sell) stock, and invest in some other small cap biotech stocks (market capitalization below $200 million) that carry an impressive Zacks Rank.

14 марта, 00:46

Time to Buy Biotech ETFs?

After a painful 2016, biotech stocks are recovering this year. What lies ahead?

13 марта, 16:32

Sarepta's DMD Drug Launch Slow; What's in Store for 2017?

We issued an updated research report on Sarepta Therapeutics, Inc. (SRPT) on Mar 9, 2016.

10 марта, 15:51

How Incyte Stock Became a Bull Market Star for Biotech Investors

Incyte (INCY) tops the list of stocks that enjoyed a stupendous run in the last 8 years.

10 марта, 11:43

Американский премаркет: участники рынка нервно курят

От вчерашнего дня ждали вроде бы многого, но… неизвестно чего. Боялись дальнейшего падения нефтяных цен, но, к счастью, падение остановилось, и даже наметился какой-то небольшой отскок.

08 марта, 16:18

Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal

Biotech stocks felt the heat once again with President Trump tweeting about competition in the drug industry and lowering drug prices.

07 марта, 14:56

Is This the Right Time to Invest in Biotech Stocks?

The biotech sector rebounded in 2017 and is on a roll since the beginning of the year -- will the rally continue?

02 марта, 22:00

Trump's Immigration Plans an Overhang on Biotech ETFs?

Immigration related uncertainty has put biotech ETFs in focus.

02 марта, 17:30

Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

02 марта, 17:05

Biotech ETF (BBH) Hits New 52-Week High

This biotech ETF hit a new 52-week high. Are more gains in store for this ETF?

02 марта, 15:15

АМКУ должно проверить решение Минздрава о предоставлении преимущества производителю дорогих лекарств - "Наш край"

Антимонопольный комитет Украины (АМКУ) должен проверить, не создало ли Министерство здравоохранения Украины благоприятные монопольные условия для производителя дорогих лекарств против гепатита "С" на украинском фармацевтическом рынке, заявил сопредседатель партии "Наш край", народный депутат Антон Кисе.

02 марта, 02:43

Pricing to Remain Pharma Headline Risk in 2017

Pricing to Remain Pharma Headline Risk in 2017

01 марта, 18:05

Sarepta (SRPT) Q4 Loss Widens; Sales of Duchenne Drug Slow

Sarepta Therapeutics, Inc. (SRPT) reported wider than expected loss in the fourth quarter of 2016.

01 марта, 15:24

Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals

Key updates this week include earnings results from companies like BioMarin and positive data on Kite's (KITE) lead pipeline candidate.